Biobanks

iSpecimen Launches Enhanced Custom Collection Service

Retrieved on: 
Thursday, July 29, 2021

LEXINGTON,Mass., July 29, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.

Key Points: 
  • LEXINGTON,Mass., July 29, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.
  • iSpecimen's Enhanced Custom Collection Service , originally intended to compensate for biospecimen collection challenges encountered during the height of the COVID-19 pandemic, was established as a way to supplement human biospecimens provided by the Company's vast network of contracted global suppliers, particularly during time-sensitive situations.
  • The enhanced service entails direct blood draws, saliva collection, and other forms of biofluid sample collections by qualified clinicians at iSpecimen headquarters.
  • Our Enhanced Custom Collection Service extends our ongoing mission of streamlining biospecimen procurement to advance medical research."

iSpecimen to Report Second Quarter 2021 Results on August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021

Participants must use the following code to access the replay of the call: 13721607.

Key Points: 
  • Participants must use the following code to access the replay of the call: 13721607.
  • An archived version of the webcast will also be available on iSpecimen's Investor Relations site: https://ispecimen.irpass.com/ .
  • iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery.
  • Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words.

Clinical Trials Laboratory Services Opens New, Larger Blood Donor Centre on Imperial College London's White City Campus

Retrieved on: 
Monday, June 21, 2021

LONDON, June 21, 2021 /PRNewswire/ -- Clinical Trials Laboratory Services (CTLS), a leading provider of human blood products and biological specimens to the research community, today announced that it has relocated its blood donor centre from Park Royal to Imperial College London's White City Campus.

Key Points: 
  • LONDON, June 21, 2021 /PRNewswire/ -- Clinical Trials Laboratory Services (CTLS), a leading provider of human blood products and biological specimens to the research community, today announced that it has relocated its blood donor centre from Park Royal to Imperial College London's White City Campus.
  • "CTLS also produces leukopaks, which contain concentrated white blood cells, and are used to conduct cell and gene therapy research.
  • "We are excited to be moving into this brand-new facility, which is four times larger than our current blood donor centre.
  • For 26 years, specimens collected at the CTLS donor centre in London have supported the development of therapeutics and in vitro diagnostic assays.

Global Biobanks Markets Report 2021-2028: Biobanks Continue to Evolve with New Technologies Such as NGS and Increased Focus on Genomic Medicine

Retrieved on: 
Tuesday, March 2, 2021

The global biobanks market size is expected to reach USD 106.9 billion by 2028 and is expected to expand at a CAGR of 6.2% from 2021 to 2028.

Key Points: 
  • The global biobanks market size is expected to reach USD 106.9 billion by 2028 and is expected to expand at a CAGR of 6.2% from 2021 to 2028.
  • Biobanks continue to evolve with the introduction of new technologies such as NGS and increased focus on genomic medicine.
  • The quality of biospecimens can significantly influence the disease testing as well as preclinical and clinical research.
  • For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples.

Biobanks (Virtual, Physical) Market Size, Share & Trends Analysis Report 2021 - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 26, 2021

The "Biobanks Market Size, Share & Trends Analysis Report by Product, by Service (Cold Chain, Lab Processing), by Biospecimen Type, by Biobank Type (Virtual, Physical), by Application, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biobanks Market Size, Share & Trends Analysis Report by Product, by Service (Cold Chain, Lab Processing), by Biospecimen Type, by Biobank Type (Virtual, Physical), by Application, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global biobanks market size is expected to reach USD 106.9 billion by 2028 and is expected to expand at a CAGR of 6.2% from 2021 to 2028.
  • Biobanks continue to evolve with the introduction of new technologies such as NGS and increased focus on genomic medicine.
  • The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market.

Worldwide Biobanking Industry to 2027 - High Growth Potential in Developing Countries

Retrieved on: 
Monday, February 15, 2021

Biobank is a biorepository meant to collect and preserve biological materials that are used for diagnosis, biodiversity studies, and research.

Key Points: 
  • Biobank is a biorepository meant to collect and preserve biological materials that are used for diagnosis, biodiversity studies, and research.
  • The rise in funding by private & government organizations for biobanking and increase in application areas of bio banked samples are the major factors that drive the growth of the global biobanking market.
  • However, ethical issues related to biobanking and lack of awareness about it are expected to impede the market growth.
  • Furthermore, government is taking multiple initiatives to support regenerative medicine research, which is expected to boost the market growth.

Global Biobanking Market (2020 to 2027) - by Specimen Type, Type of Biobank, Ownership, and Application - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021

The "Biobanking Market by Specimen Type, Type of Biobank, Ownership, and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biobanking Market by Specimen Type, Type of Biobank, Ownership, and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The rise in funding by private & government organizations for biobanking and increase in application areas of bio banked samples are the major factors that drive the growth of the global biobanking market.
  • However, ethical issues related to biobanking and lack of awareness about it are expected to impede the market growth.
  • The global biobanking market is segmented into specimen type, type of biobank, ownership, application, and region.

DNA & RNA Banking Services Market Size Worth $8.83 Billion By 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, February 3, 2021

SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ --The global DNA and RNA banking services market size is expected to reach USD 8.83 billion by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ --The global DNA and RNA banking services market size is expected to reach USD 8.83 billion by 2027, according to a new report by Grand View Research, Inc.
  • Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providing a path for the expansion of personalized medicine.
  • The development of automated solutions and the transformation of biobanks into fully automated biobanks potentially accelerate the growth of the market.
  • Grand View Research has segmented the global DNA and RNA banking services market on the basis of service type, specimen type, application, end-use, and region:
    DNA & RNA Banking Service Type Outlook (Revenue, USD Million, 2016 - 2027)

DNA & RNA Banking Services Market Size Worth $8.83 Billion By 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, February 3, 2021

SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ --The global DNA and RNA banking services market size is expected to reach USD 8.83 billion by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ --The global DNA and RNA banking services market size is expected to reach USD 8.83 billion by 2027, according to a new report by Grand View Research, Inc.
  • Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providing a path for the expansion of personalized medicine.
  • The development of automated solutions and the transformation of biobanks into fully automated biobanks potentially accelerate the growth of the market.
  • Grand View Research has segmented the global DNA and RNA banking services market on the basis of service type, specimen type, application, end-use, and region:
    DNA & RNA Banking Service Type Outlook (Revenue, USD Million, 2016 - 2027)

Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature

Retrieved on: 
Tuesday, December 15, 2020

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood collection device (BCD).

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood collection device (BCD).
  • In light of ongoing blood supply shortages and logistical challenges, Biodesix believes that the BCD could offer significant value for companies engaged in blood collection.
  • The blood collection device has allowed us to create efficiencies in sample collection processes for two of our tests, and will support our future proteomic products.
  • Once dried, the specimen can be transported under ambient conditions to laboratories for diagnostic as well as for research use.